CN1390222A - 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物 - Google Patents

作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物 Download PDF

Info

Publication number
CN1390222A
CN1390222A CN00815534A CN00815534A CN1390222A CN 1390222 A CN1390222 A CN 1390222A CN 00815534 A CN00815534 A CN 00815534A CN 00815534 A CN00815534 A CN 00815534A CN 1390222 A CN1390222 A CN 1390222A
Authority
CN
China
Prior art keywords
formula
medicine
compound
acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00815534A
Other languages
English (en)
Chinese (zh)
Inventor
H·M·艾根维勒
R·乔纳斯
M·沃尔夫
M·加森
T·维尔戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1390222A publication Critical patent/CN1390222A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
CN00815534A 1999-11-13 2000-10-31 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物 Pending CN1390222A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954707.6 1999-11-13
DE19954707A DE19954707A1 (de) 1999-11-13 1999-11-13 Imidazolverbindungen als Phosphodiesterase VII-Hemmer

Publications (1)

Publication Number Publication Date
CN1390222A true CN1390222A (zh) 2003-01-08

Family

ID=7928973

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00815534A Pending CN1390222A (zh) 1999-11-13 2000-10-31 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物

Country Status (23)

Country Link
US (1) US6884800B1 (https=)
EP (1) EP1228073B1 (https=)
JP (1) JP4819272B2 (https=)
KR (1) KR20020049051A (https=)
CN (1) CN1390222A (https=)
AR (1) AR026421A1 (https=)
AT (1) ATE245653T1 (https=)
AU (1) AU775886B2 (https=)
BR (1) BR0015487A (https=)
CA (1) CA2391087A1 (https=)
CZ (1) CZ20021474A3 (https=)
DE (2) DE19954707A1 (https=)
DK (1) DK1228073T3 (https=)
ES (1) ES2200968T3 (https=)
HU (1) HUP0203422A3 (https=)
MX (1) MXPA02004728A (https=)
NO (1) NO20022232L (https=)
PL (1) PL355098A1 (https=)
PT (1) PT1228073E (https=)
RU (1) RU2002113759A (https=)
SK (1) SK6012002A3 (https=)
WO (1) WO2001036425A2 (https=)
ZA (1) ZA200204729B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809001B (zh) * 2007-10-05 2012-12-12 默克专利有限公司 咪唑衍生物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ628054A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
IL318817A (en) 2022-08-18 2025-04-01 Mitodicure Gmbh Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919271A (en) * 1957-12-05 1959-12-29 Smith Kline French Lab 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
CA2051697C (en) * 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809001B (zh) * 2007-10-05 2012-12-12 默克专利有限公司 咪唑衍生物

Also Published As

Publication number Publication date
EP1228073B1 (de) 2003-07-23
ATE245653T1 (de) 2003-08-15
AR026421A1 (es) 2003-02-12
CA2391087A1 (en) 2001-05-25
JP2003514821A (ja) 2003-04-22
DK1228073T3 (da) 2003-11-03
DE50003036D1 (de) 2003-08-28
WO2001036425A2 (de) 2001-05-25
MXPA02004728A (es) 2002-08-30
CZ20021474A3 (cs) 2002-07-17
JP4819272B2 (ja) 2011-11-24
KR20020049051A (ko) 2002-06-24
RU2002113759A (ru) 2004-01-10
DE19954707A1 (de) 2001-05-17
HUP0203422A3 (en) 2004-12-28
ES2200968T3 (es) 2004-03-16
US6884800B1 (en) 2005-04-26
NO20022232D0 (no) 2002-05-10
NO20022232L (no) 2002-05-10
SK6012002A3 (en) 2002-09-10
EP1228073A2 (de) 2002-08-07
AU775886B2 (en) 2004-08-19
WO2001036425A3 (de) 2002-01-10
HUP0203422A2 (hu) 2003-02-28
PL355098A1 (en) 2004-04-05
AU1390701A (en) 2001-05-30
BR0015487A (pt) 2002-07-02
PT1228073E (pt) 2003-12-31
ZA200204729B (en) 2003-11-26

Similar Documents

Publication Publication Date Title
CN1390222A (zh) 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物
US5571809A (en) The treatment of HIV-1 infection using certain pyridodiazepines
HK1049831A1 (zh) 作為磷酸二酯酶vii抑制劑的吡咯衍生物
CN1387530A (zh) 用作磷酸二酯酶vii抑制剂的咪唑并吡啶衍生物
SK282116B6 (sk) Derivát imidazopyridínu, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
KR100673638B1 (ko) 아릴 알카노일피리다진류
EP0784624A1 (en) Purine and guanine compounds as inhibitors of pnp
EP1467996A1 (en) Pyrimidotriazines as phosphatase inhibitors
TW202539684A (zh) 一種三唑並嘧啶類衍生物、其製備方法與應用
JP2656133B2 (ja) ６，１１―ジヒドロ―５Ｈ―ピリド［２，３―ｂ］［１，５］ベンゾジアゼピン―５―オン及び―チオン並びに該化合物のＡＩＤＳの予防又は治療における使用法
JP2862980B2 (ja) ジベンズ〔ｂ，ｆ〕〔１，４〕オキサゼピン（及び―チアゼピン）―１１（１０Ｈ）―オン又は―チオン類を含有するエイズの予防もしくは治療用医薬組成物
CA2388314C (en) Imidazole derivatives as phosphodiesterase vii inhibitors
HK1051364A (en) Imidazole compounds used as phosphodiesterase vii inhibitors
WO1998030559A1 (en) Process for the production of tetrazolylbenzopyrans
US20080058368A1 (en) 4,5,6,7-Tetrahydro-[1,2]Dithiolo[4,3-C] Pyridine-3-Thione Compounds
HK1050366A (en) Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
CN114127078A (zh) 杂化合物及其使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1051364

Country of ref document: HK